글로벌 망막 질환 치료제 시장 – 2030년까지의 산업 동향 및 예측

망막 질환 치료제 시장 분석 및 규모

망막은 눈의 뒤쪽 끝에 위치한 섬세한 조직층으로, 빛을 감지하고 이미지를 뇌로 전송하는 역할을 합니다. 모든 형태의 망막 장애는 이 섬세한 조직을 손상시키고 시력에 영향을 미치며 심각한 경우 실명으로 이어질 수 있습니다. 망막 장애는 유전적이거나 연령과 관련이 있어 시력에 퇴행성 변화를 일으킬 수 있습니다. 그러나 망막 검사는 유전적 망막 장애에 대한 유전자 검사 와 함께 잠재적 질병을 진단하는 첫 번째 단계입니다 .

망막 질환은 노령 인구와 당뇨병 환자 모두에게서 유병률과 발생률이 높으므로 성인 및 당뇨병 환자 인구가 증가하면 망막 질환 치료 시장도 활성화될 것입니다.

Data Bridge Market Research는 2022년에 125억 7천만 달러였던 망막 질환 치료제 시장이 2030년까지 256억 9천만 달러로 성장할 것으로 분석했으며, 예측 기간 동안 9.3%의 CAGR을 기록할 것으로 예상합니다. "황반변성"은 유병률이 높아 망막 질환 치료제 시장의 장애 부문을 지배합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

망막 질환 치료제 시장 범위 및 세분화

Market Definition

Retinal diseases are a group of medical conditions that affect the retina, which is the light-sensitive tissue located at the back of the eye. These diseases can disrupt the normal functioning of the retina, leading to vision impairment or even blindness. Common retinal diseases include macular degeneration, diabetic retinopathy, retinal detachment, retinitis pigmentosa, and others. Therapeutics for retinal diseases aim to manage and treat these conditions to preserve or improve a patient's vision. Treatment approaches can vary depending on the specific disease and its severity but may include medications, laser therapy, surgery, and implantable devices among others.

Retinal Disease Therapeutics Market Dynamics

Drivers

• Aging Population

The aging population is more susceptible to retinal diseases, such as age-related macular degeneration (AMD). As the global population continues to age, the prevalence of retinal diseases is expected to increase, driving the demand for therapeutics

• Rising Incidence of Diabetes

Diabetic retinopathy is a common retinal disease associated with diabetes. The increasing incidence of diabetes worldwide is a significant driver of the retinal disease therapeutics market

Opportunities

• Medical Research and Development

Increased demand for retinal disease treatments will drive research and development efforts. This presents opportunities for pharmaceutical and biotech companies to innovate and develop new drugs and therapies for retinal diseases

• Technological Advancements

As the market grows, there will be a greater need for advanced diagnostic and treatment technologies. This creates opportunities for companies involved in developing cutting-edge medical devices and imaging technologies for retinal diseases

Restraints/Challenges

• High Cost of Treatment

The cost of some retinal disease treatments, including anti-VEGF drugs and surgical interventions, can be prohibitively expensive. This cost burden can limit access to these therapies for some patients

• Limited Efficacy of Current Treatments

While significant progress has been made, some retinal diseases still lack highly effective treatments. For instance, advanced stages of certain diseases such as retinitis pigmentosa may have limited therapeutic options

This retinal disease therapeutics Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Retinal disease therapeutics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Development

• In October 2022, in a 600% million deal, Boehringer Ingelheim targets Surrozen’s preclinical disease asset. Surrozen has caught the attention of Boehringer Ingelheim, which paid the California biotech USD 12.5 million upfront for its preclinical asset designed to regenerate healthy eye tissue and potentially reverse retinal disease

Global Retinal Disease Therapeutics Market Scope

The retinal disease therapeutics Market is segmented on the basis of disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disorder

• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Disorder Type

• Genetic
• Age Related

Treatment Techniques

• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Route of Administration

• Oral
• Topical
• Intravitreal
• Others

End-Users

• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Regional Analysis/Insights

The retinal disease therapeutics market is analyzed and market size insights and trends are provided by disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel as referenced above.

The countries covered in the retinal disease therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America accounts for the largest market share due to the high healthcare expenditure and good quality medical facilities along with the majority of population have insurance cover to claim this type of expensive treatment.

Asia-Pacific region is expected to record the fastest growth during the forecast period due to increasing patient pool, improving public and private reimbursement infrastructure, and constant development of healthcare facilities.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Retinal Disease Therapeutics Market Share Analysis

망막 질환 치료제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 망막 질환 치료제 시장과 관련된 회사의 초점에만 관련이 있습니다.

망막 질환 치료제 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 산텐제약 주식회사(일본)
• Bausch Health Companies Inc. (캐나다)
• Sentis Pharma Pvt Ltd.(인도)
• F. 호프만-라 로슈 유한회사(스위스)
• 존슨앤존슨 서비스 주식회사(미국)
• 노바티스 AG(스위스)
• 애브비(미국)
• Regeneron Pharmaceuticals, Inc. (미국)
• 아콘(미국)
• Mitotech, SA(러시아)
• 쿠보타제약홀딩스 주식회사(일본)
• 그레이버그 비전 주식회사(미국)
• Sun Pharmaceutical Industries Ltd. (인도)
• 오츠카제약 주식회사(일본)
• 센주제약 주식회사(일본)
• Valent Pharmaceuticals North America LLC(미국)
• 제넨텍 주식회사(미국)
• 눈 치료(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 칼라제약(미국)
• 아이벤시스(프랑스)
• 알데이라 테라퓨틱스(Aldeyra Therapeutics, Inc.) (미국)

SKU-60084